**“Test n Treat” (TnT): a cluster randomised feasibility trial of on-site rapid *Chlamydia trachomatis* tests and treatment in ethnically diverse, sexually active teenagers attending technical colleges**

1Pippa Oakeshott oakeshot@sgul.ac.uk

1Sarah Kerry-Barnard srkerry@sgul.ac.uk

1Charlotte Fleming crdfleming@gmail.com

2Rachel Phillips [r.phillips@imperial.ac.uk](mailto:r.phillips@imperial.ac.uk)

3Vari M Drennan V.Drennan@sgul.kingston.ac.uk

4Elisabeth J Adams [elisabeth.adams@aquariusph.com](mailto:elisabeth.adams@aquariusph.com)

5Wendy Majewska wendy@wemconsultancy.com

6,7Emma M Harding-Esch Emma.Harding-Esch@lshtm.ac.uk

6Emma C Cousins [E.Cousins@soton.ac.uk](mailto:E.Cousins@soton.ac.uk)

6Tim Planche tplanche@sgul.ac.uk

1Alastair Green m1400086@sgul.ac.uk

1Rosalie I Bartholomew [rosalie.bartholomew@nhs.net](mailto:rosalie.bartholomew@nhs.net)

6S Tariq Sadiq [ssadiq@sgul.ac.uk](mailto:ssadiq@sgul.ac.uk)

2Fiona Reid [fiona.reid@kcl.ac.uk](mailto:fiona.reid@kcl.ac.uk)

1Population Health Research Institute

St George’s, University of London, SW17 0RE

2School of Population Health and Environmental Sciences

King’s College London, SE1 1UL

3Centre for Health & Social Care Research,

Kingston University & St George's, University of London, SW17 0RE

|  |
| --- |
| 4Aquarius Population Health Limited |
| [**58a Highgate High Street, London, UK N6 5HX**](https://www.google.com/maps/place/58a+Highgate+High+Street,+London,+UK+N6+5HX) |
| 5WEM Consultancy Ltd. 96 Tantallon Road, London, SW12 8DH |

6Institute for Infection and Immunity

St George’s, University of London, SW17 0RE

7Public Health England

61 Colindale Avenue, London, NW9 5EQ

Correspondence to Professor Oakeshott [oakeshot@sgul.ac.uk](mailto:oakeshot@sgul.ac.uk)

**Abstract**

**Objectives** We conducted a cluster-randomised feasibility trial of 90-minute *Chlamydia trachomatis* tests and same day on-site treatment (“Test n Treat/TnT”) in six technical colleges in London, England to assess:

* TnT uptake rates
* Follow-up rates
* Prevalence of *C.trachomatis* at baseline and 7-months
* Time to treatment
* Acceptability of TnT

**Methods**

Participants completed questionnaires and provided genitourinary samples at baseline and seven months. Participants were informed that baseline samples would not be tested for 7- months and advised to get screened independently. Colleges were randomly allocated 1:1 to intervention (TnT) or control (no TnT).

One and 4-months post-recruitment, participants at intervention colleges were texted invitations for on-site free *C.trachomatis* tests. A purposive sample of students who did/did not attend for screening were interviewed (n=26).

**Results**

509 sexually active students were recruited: median age 17.9 years, 47% male, 50% black ethnicity, 55% reporting ≥2 sexual partners in the previous year. TnT uptake was 13% (33/259; 95% CI 8.9-17.4%) at one month and 10% (26/259;6.7-14.4%) at 4-months with overall *C.trachomatis* positivity 5.1% (3/59;1.1-14.2%). Follow-up at 7-months was 62% (317/509) for questionnaires and 52% (264/509) for samples. *C.trachomatis* prevalence was 6.3% (31/503) at baseline and 6.1% (16/264) at 7-months. Median time from test-to-treatment was 15-hours. Interviews suggested low test uptake was associated with not feeling at risk, perceptions of stigma and little knowledge of sexually transmitted infections (STIs).

**Conclusions**

Despite high *C.trachomatis* rates at baseline and follow-up, uptake of testing was low. Like many countries, England urgently needs better sex education, including making STI testing routine/normal.

**Trial registration** ISRCTN58038795

**Key words**

Rapid *C.trachomatis* tests

Screening

Young people

Technical colleges

Test and treat

Cluster randomised

Feasibility trial

**Introduction**

*Chlamydia trachomatis* is a common, often asymptomatic, bacterial sexually transmitted infection (STI) which can lead to pelvic inflammatory disease, ectopic pregnancy and infertility [1] [2] and may be associated with adverse pregnancy outcomes [3]. However, uptake of *C.trachomatis* testing by 16-24 year olds in many countries is too low to reduce infection rates [4-8] [1], and there are often delays in treatment. Bringing novel 90-minute *C.trachomatis* tests [9] [10] and same day on-site treatment (“TnT=Test n Treat”) to the community might get more young people treated faster [6, 10]. This could reduce rates of infection, onward transmission and adverse reproductive health effects, and save healthcare costs [7, 11].

In order to address a number of unknown parameters required for the design of a future definitive study, we conducted a cluster randomised feasibility trial (or pilot study) of frequent, rapid TnT in six technical (“Further Education”/ FE) colleges in London, England over the academic year 2016-17. (FE colleges offer both academic and practical courses such as plumbing and hairdressing, and take many students from socio-economically deprived backgrounds.  *C.trachomatis* positivity may be 6-8% [12-14].)

We assessed the following feasibility outcomes:

* Recruitment rates
* TnT uptake rates
* Follow-up rates
* Prevalence of *C.trachomatis* at baseline and 7 months
* Time to treatment
* Acceptability of TnT

We selected a cluster design for practical reasons for delivering screening, which would reflect the design of a definitive trial. This was a feasibility study and was not powered to assess the effectiveness of TnT. Although we used a combined *C.trachomatis*/*Neisseria gonorrhoeae* rapid test (Cepheid CT/NG GeneXpert® system [9]), on-site treatment (TnT) was for individuals with *C.trachomatis* only [15] as participants with *N.gonorrhoeae* (or *C.trachomatis*/*N.gonorrhoeae* dual infection) were referred to a sexual health clinic. Detailed qualitative and economic analyses will be presented elsewhere.

**Methods**

*Recruitment and baseline samples*

All technical colleges/clusters were eligible and all six approached agreed to participate. As previously described [15], researchers recruited students from public areas at the six colleges. Students were eligible if they were aged 16-24 and had ever had sexual intercourse. The participant information leaflet and consent form provided information about STIs and the study design (supplementary files). Participants provided written informed consent. They were asked to complete questionnaires (see Table 1), and to provide samples (for research purposes only) in the nearest washroom (urines for males, self-collected vaginal swabs for females) [15]. These samples were stored at -80 °C and tested blind at St George’s hospital after seven months using the Cobas 4800 CT/NG system (Roche diagnostics) [7]. All participants were warned of the risks of untreated *C.trachomatis*/*N.gonorrhoeae* and that their baseline samples would not be tested for seven months, and advised to get checked for STIs independently of the study.

*Randomisation*

After recruitment of all participants, the six colleges were randomly allocated 1:1 into the intervention group (TnT) or control group (no TnT, **Figure 1**) by the trial statistician using a computer-generated allocation sequence [15].

*Intervention colleges: TnT at both one and four months*

One and four months after recruitment (to fit with college Autumn and Spring terms), each of the three intervention colleges were visited on two consecutive days by the research team. We advertised the visit on college websites and notice boards, and texted/emailed participating students the day before the visit and on both days inviting them to come for TnT. Attendees came to a private room to collect a test kit. When they returned with a sample, it was tested for *C.trachomatis*/*N.gonorrhoeae* immediately on-site in a pop-up lab in a classroom using a 90-minute test [15] (one test/participant). Negative results were texted to participants. The research team’s nurse health-adviser telephoned participants with positive results and met them in another private room in college (same-day whenever possible) for confidential treatment for *C.trachomatis*, partner notification and/or referral.

*Control colleges: no TnT*

Participants from the three control colleges received texts one and four months after recruitment thanking them for being in the study.

*Outcome assessment at 7 months*

All six colleges were visited again on two consecutive days in the summer term using the same methods as in TnT above, and participants from both groups were invited to provide repeat questionnaires and samples for immediate testing. Same day results and treatment were provided for all attenders (but these were not part of the TnT intervention). Non-attenders were followed up by text/email and telephone questionnaire and asked to give an address (eg home/work/college) if they were willing to provide a postal sample for testing [15].

*Honoraria*

Participants received £5 in cash when they returned samples at recruitment and £10 after providing samples at seven months follow-up. Participants in intervention colleges did not receive honoraria for attending for TnT at one and four months, as in the UK people are not usually paid for having an STI test.

*Masking*

Recruitment of colleges and participants was conducted blind to group allocation. After the first TnT intervention, participants and researchers were no longer blinded.

*Main outcome measures* (key values to inform feasibility, sample size and timescales of a definitive trial)

* Recruitment rates
* TnT uptake in intervention participants at one and four-months
* Follow-up rates at seven-months
* Prevalence of *C.trachomatis* at baseline and seven-months
* Time to receiving results and treatment (fidelity of TnT)
* Acceptability of TnT in intervention colleges from thematically-analysed semi-structured interviews[16] with purposively sampled students (n=26 to ensure a range of ages, genders and ethnicities) who did/did not attend for TnT (to be published elsewhere).

*Sample size and statistical analysis*

Sixty to 100 subjects is sufficient to estimate an event rate with acceptable precision (i.e. sufficiently narrow confidence intervals) in a feasibility study [17] [15]. As previously described [18], assuming a 30% recruitment rate [13], we aimed to approach 1600 students to recruit 480 overall (80 per college across 6 colleges).

Progression criteria to a definitive trial were: TnT uptake ≥60% [13] at 1 and 4-months and TnT being acceptable to participants [16] (intervention colleges only), and follow-up rate ≥70% [12] at 7-months (all colleges).

Since this was a feasibility study, no significance testing was performed [19]. Descriptive statistics are presented, with corresponding exact 95% confidence intervals. Analyses [18] were performed in Stata version 14. As our analysis was of feasibility outcomes, the sample size and analysis were not adjusted for clustering.

**Ethics approval and consent to participate**

Bromley REC reviewed the study (reference 15/LO/1929). Parental consent for 16-18 year-olds was not required.

**Results**

*Recruitment*

Over three weeks in September/October 2016 we recruited 509 participants from six colleges (range 78-90 per college). We were unable to obtain information on all non-participants, but completed recruitment forms for 180 non-participants suggested that 67% (121/180) were ineligible due to never having had sexual intercourse, 14% (25/180) were ineligible for other reasons (e.g. not aged 16-24), and 19% (34/180) were eligible but declined.

Participants’ median age was 17.9 years and 90% (458) were teenagers (aged 16-19 years). Participants described their ethnicity as black (50%), white (26%) or other ethnic groups (24%). Approximately half (47%, 240) were male, including 117 (23%) black male teenagers. Over half (55%) reported ≥2 sexual partners in the previous year, and a third (36%) said they had been tested for STIs in the past 6 months. Eligible non-participants (n=34) were similar to participants in age and ethnicity (median age 17, IQR 17-19; 53% black ethnicity), but a slightly higher proportion (67%) were male. Table 1 shows baseline characteristics of participants from intervention and control colleges.

*TnT uptake at one and four months in intervention colleges*

Thirteen percent (33/259; 95% CI 8.9-17.4%) of intervention participants attended for on-site rapid tests and provided samples at one month, and 10% (26/259; 95% CI 6.7-14.4%) at four months despite implementing changes suggested by students and staff to increase uptake. These included brief information for tutors to give to their tutorial groups, educational posters (supplementary files), user-friendly texts and free condoms. Five students provided samples at both one and four months. Of 59 tests, three (5.1%, 1.1-14.2) were positive for *C.trachomatis*. Two students with *C.trachomatis* only were treated on-site (one same day, one next day), and one with dual *C.trachomatis*/*N.gonorrhoeae* infection was referred for treatment as per protocol. Table 2 shows baseline characteristics of participants who did/did not provide samples for TnT were broadly similar, although more TnT attenders than non-attenders had a history of *C.trachomatis* (13% versus 6%), and more were men who had sex with men (MSM, 15% versus 3%).

*Follow-up*

Overall follow-up at seven months was 62% (317/509; 95% CI 58-67%) for questionnaires and 52% (264/509; 95% CI 47-56%) for samples. (A further four participants provided invalid samples: three with no human DNA, one delayed postal sample.) Almost half the participants (46%, 232/509) completed follow-up questionnaires at college, a further 9% (46/509) subsequently completed an online questionnaire and 8% (39/509) a brief telephone questionnaire. These showed 29% of intervention participants and 25% of control participants reported STI testing outside the trial. (Other study-related behaviours reported at follow-up are shown in Table 3). Valid samples for testing were provided at college by 229 (45%) participants and later by post by a further 35 (7%) participants. Supplementary Table 1 gives baseline characteristics of those who did/did not provide samples at seven months follow-up.

*Prevalence of C.trachomatis/N.gonorrhoeae at baseline and 7-months*

Prevalences of *C.trachomatis* and *N.gonorrhoeae* respectively were 6.2% (31/503; 4.2-8.6%) and 0.6% (3/503, 0.1-1.7%) at baseline (six samples were discarded as mislabelled). Prevalences at follow-up were: *C.trachomatis* 6.1% (16/264, 3.5-9.7%, including 15 *C.trachomatis* only positive samples [13 college, 2 postal] and one dual infection); and *N.gonorrhoeae* 1.1% (3/264, 0.2-3.3%, including the dual infection). The prevalence of *C.trachomatis* in males and females was 6.8% (16/236) and 5.6% (15/267) at baseline; and 3.2% (4/125) and 8.6% (12/139) at follow-up. The three cases of *N.gonorrhoeae* at baseline were in males, the three at follow-up were in females. Prevalence of *C.trachomatis* in those tested at each college ranged from 1.3%-8.4% at baseline (intraclass correlation coefficient 0.002), and 2.4%-10.4% at follow-up (Supplementary Table 2).

*Time to results and treatment*

For samples provided at college at one, four and seven months, most results (90%, 259/288) were received by participants the same day. Median time to being informed of a negative result (n=267) was 2.1 hours (IQR 1.8-2.7 hours, range 1.5 hours to 23 days due to an administrative error). For the 15 cases of *C.trachomatis* only which were diagnosed in college (2+13 at months one/four and seven respectively), ten were treated on-site (6 same day, 4 next day), three were confirmed treated later elsewhere (timing unclear for one), and two were not confirmed treated. Median time to confirmed treatment for *C.trachomatis* only (n=12) was 14.6 hours (IQR 2.4-26.3 hours, range 1.7 hours-27 days due to a problem with a mobile number).

*Acceptability*

Semi-structured interviews in January-March 2017 with 13 students who attended for TnT and 13 who did not, suggested that low uptake of TnT was associated with not feeling at risk, perceptions of stigma and lack of knowledge about STIs. However, all were positive about TnT: “I think the service you provide is actually very good because like most kids I think they would be too shy to like go out and get checked….” (male, 16, black, TnT non-attender). Comments from attenders included: “amazing”, “educational”, “friendly”, “helpful”.

**Discussion**

*Principal findings*

Rapid recruitment of sexually active teenagers was possible with £5 honoraria. However, despite high rates of *C.trachomatis* at both baseline and follow-up, the proportion of participants attending for non-incentivised college-based TnT was low: 13% at one month and 10% at four months. Although predetermined progression criteria for a definitive trial were not met, findings provide important insights for designing future studies and for public health policy.

*Strengths and weaknesses*

This was a unique study in a group of often socio-economically deprived, ethnically diverse, inner city teenagers. It included >100 black, sexually experienced teenage males, a group not often included in European STI research studies [4, 7]. Participants had high rates of undiagnosed STIs including six participants with heterosexual *N.gonorrhoeae*, all from black and minority ethnic groups. It is also the first randomised study of rapid tests with on-site *C.trachomatis* treatment in FE colleges. It was a pragmatic study in a relevant setting to reach sexually active young people. Data on teenage lifestyles may inform future studies.

There are limitations. Opportunistic recruitment meant it was difficult to calculate a recruitment rate. We could not use the college population aged 16-24 (range approximately 500-3000 per college) as the denominator because assessment of eligibility required information on sexual history. As in other studies [4, 20] we used self-reported data, which is subject to inaccurate recall. However, reported history of *C.trachomatis* was similar to rates in 16-24 year old Londoners taking part in the population-based National Surveys of Sexual Attitudes and Lifestyles (8.2%, 41/502 in our study versus 7.0%, 19/273 in Natsal-3 UK data archive). Only two-thirds (10/15) of *C.trachomatis* only positives diagnosed in college were treated on-site. A faster 30 minute test might have encouraged more students to wait for results[21], but no such suitable test was available. Although all participants diagnosed with infections were informed that their partners needed treatment, we did not have partners’ consent to confirm notification. The study design meant TnT was only available to those already recruited. This would not happen if TnT were rolled out in routine practice. Follow-up rates were lower than the 81% in the recent “Safetxt” pilot trial[22], but most of their participants were white, and/or aged 20-24. Our findings may not apply to such groups.

*Comparison with other studies*

Rates of testing were lower than (54-60%) expected from our FE college-based pilot work[13, 16, 23], but similar to that in 16-29 year olds in a large Dutch register-based *C.trachomatis* screening trial: 16% in the first round decreasing to 11% in the second[8] with no substantial decrease in STI positivity rates. Another study from a Scottish FE college found 17% *C.trachomatis* testing uptake in teenagers[24] suggesting this is a challenging group to engage. By contrast, in the French Chlamyweb study [7] uptake by 18-24 year olds of an online offer of home-based *C.trachomatis* testing was 24% in males and 34% in females with positivity rates of 4.4% and 8.3% respectively. Similarly, in “SH24”, internet accessed postal testing almost doubled uptake of STI testing [20]. However most participants were white and/or aged 20-30 years. As in other studies [7] [16] many of our teenage participants did not want a test kit posted to their home. The high *C.trachomatis* positivity rates in Chlamyweb and our study were similar to those observed in STI clinics [7] and roughly double the rates in population-based studies in sexually-experienced males and females aged 16-24 in England [5] (2.3% and 3.1%) and USA [25] (1.7% and 3.2% respectively). Finally, there were more MSM among TnT attenders than non-attenders. MSM may be more aware of STI prevention [20].

The median time from diagnosis to treatment (within one day) was similar to a recent feasibility study of online *C.trachomatis* management via an eSexual health clinic [26]. Overall rates of confirmed treatment for *C.trachomatis* (87%, 13/15) were similar to ChlamywebII [7] (87%, 58/67) and 2014 English National Chlamydia Screening Programme results (91% within six weeks of test date [27]). Participants’ lack of knowledge about STIs was in line with community-based studies from USA, Europe and Australia [28] [29] [16, 24, 30]. Sex education is optional in English state secondary schools.

*Conclusions and perspectives*

The low uptake of TnT despite high rates of STIs suggests that a definitive trial of TnT using this design is not feasible in FE colleges. It highlights both the difficulties of designing studies to reach sexually active young people, and the crucial need for better sex and relationships education [2]. This should include “normalisation” of STI testing [20] making it routine/acceptable to get checked. However, accessing testing is often problematic [1]. In the UK, funding cuts have closed many sexual health clinics, and relying on internet postal testing may disadvantage vulnerable teenagers [20]. Future trials might evaluate college-wide, multicomponent, combined Education/TnT interventions. This could include lessons offering user-friendly information on STIs, free condoms and postal test kits perhaps followed by pop-up clinics offering confidential, on-site TnT.

**Funding**

This independent research is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number **PB-PG-1014-35007**). Value in kind funding was received from the UKCRC Translational Infection Research Initiative supported by the Medical Research Council (Grant Number G0901608) with contributions from the Biotechnology and Biological Sciences Research Council and the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funding body had no role in the design of the study, the collection, analysis or interpretation of the data, or the write-up of the manuscript.

**Availability of data and materials**

Data and materials may be obtained from trial manager SKB.

**Authors’ contributions**

PO, FR, STS, VMD, EA and SKB designed the study and obtained the funding. FR and RP designed the statistical analysis plan and analysed the data with trial manager SKB. PO wrote the first draft of the paper to which all authors then contributed. All authors read and approved the final manuscript.

**Competing interests**

Pippa Oakeshott is a member of the NIHR South London Collaboration for Leadership in Applied Health Research and Care. PO, STS, EHE and EC are members of the *e*STI2 consortium funded under the UKCRC Translational Infection Research Initiative. STS, EHE and EC are members of the Applied Diagnostic Research and Evaluation Unit and have received funding for projects from Cepheid, Atlas Genetics, TwistDx. Elisabeth Adams is employed by Aquarius Population Health that receives grants and other funding to work on projects relating to STIs and point of care tests. Fiona Reid is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.

**Acknowledgements:** We thank Georgie Timson and Alice Bonnissent of Cepheid International for providing the rapid *C.trachomatis/N.gonorrhoeae* tests, and Agata Lesniewska for doing *C.trachomatis*/*N.gonorrhoeae* tests on the stored baseline samples. We confirm Cepheid had no role in the design of the study, the collection, analysis or interpretation of the data, or the write-up of the manuscript.

The Clinical Research Network nurses helped with consenting participants.

Preventx tested postal samples.

We also thank students and staff at the participating London FE colleges: Lambeth, Kingston, Merton, Wandsworth, Southwark and Lewisham.

Reference List

(1) Centers for Disease Control. Sexually transmitted disease surveillance 2016. US Department of Health and Human Services; 2017.

(2) Public Health England. Sexually transmitted infections and chlamydia screening in England 2016. Health Protection Report 2017; 11(20).

(3) Reid F, Oakeshott P, Kerry SR, Hay PE, Jensen JS. Chlamydia related bacteria (Chlamydiales) in early pregnancy: community-based cohort study. Clin Microbiol Infect 2017; 23:119-24.

(4) Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382(9907):1795-806.

(5) Woodhall SC, Soldan K, Sonnenberg P, et al. Is chlamydia screening and testing in Britain reaching young adults at risk of infection? Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm Infect 2016; 92(3):218-27.

(6) Guy RJ, Natoli L, Ward J, et al. A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the "TTANGO" trial protocol. BMC Infect Dis 2013; 13:485.

(7) Kersaudy-Rahib D, Lydie N, Leroy C, et al. Chlamyweb Study II: a randomised controlled trial (RCT) of an online offer of home-based Chlamydia trachomatis sampling in France. Sex Transm Infect 2017; 93(3):188-95.

(8) van den Broek IV, van Bergen JE, Brouwers EE, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. BMJ 2012; 345:e4316.

(9) Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013; 51(6):1666-72.

(10) Causer LM, Guy RJ, Tabrizi SN, et al. Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sex Transm Infect 2018.

(11) Turner KM, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect 2014; 90(2):104-11.

(12) Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. Br Med J 2010; 340:1642.

(13) Balendra A, Cousins E, Lamplough H, Oakeshott P, Majewska W, Kerry SR. Pilot study for the 'Test n Treat' trial of on-site rapid chlamydia/gonorrhoea tests and same day treatment. Sex Transm Infect 2017; 93(4):283.

(14) Sharman N, Sri T, Chow C, et al. Chlamydia testing: Reaching high-risk sexually active young people in the community. Int J STD AIDS 2016; 27(1):78-9.

(15) Kerry-Barnard S, Fleming C, Reid F, et al. 'Test n Treat (TnT)'- Rapid testing and same-day, on-site treatment to reduce rates of chlamydia in sexually active further education college students: study protocol for a cluster randomised feasibility trial. Trials 2018; 19(1):311.

(16) Normansell R, Drennan VM, Oakeshott P. Exploring access and attitudes to regular sexually transmitted infection screening: the views of young, multi-ethnic, inner-city, female students. Health Expect 2015; PM:25703741.

(17) Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials 2014; 15:264.

(18) Phillips R, Oakeshott P, Kerry-Barnard S, Reid F. 'Test n Treat (TnT)': a cluster-randomised feasibility trial of frequent, rapid-testing and same-day, on-site treatment to reduce rates of chlamydia in high-risk further education college students: statistical analysis plan. Trials 2018; 19(1):312.

(19) Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res 2011; 45(5):626-9.

(20) Wilson E, Free C, Morris TP, et al. Internet-accessed sexually transmitted infection (e-STI) testing and results service: A randomised, single-blind, controlled trial. PLoS Med 2017; 14(12):e1002479.

(21) Harding-Esch EM, Cousins E, Sadiq ST. A 30-Min Nucleic Acid Amplification Point-of-Care Test for Genital Chlamydia trachomatis Infection in Women: A Prospective, Multi-centre Study of Diagnostic Accuracy. ebiomedicine 2018; 28:120-7.

(22) McCarthy OL, French RS, Baraitser P, et al. Safetxt: a pilot randomised controlled trial of an intervention delivered by mobile phone to increase safer sex behaviours in young people. BMJ Open 2016; 6(12):e013045.

(23) Holland J, Oakeshott P. Chlamydia testing in male further education college students. Sex Transm Infect 2015; 91(7):496.

(24) Lorimer K, Reid ME, Hart GJ. Willingness of young men and women to be tested for Chlamydia trachomatis in three non-medical settings in Glasgow, UK. J Fam Plann Reprod Health Care 2009; 35(1):21-6.

(25) Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40(3):187-93.

(26) Estcourt CS, Gibbs J, Sutcliffe LJ, et al. The eSexual Health Clinic system for management, prevention, and control of sexually transmitted infections: exploratory studies in people testing for Chlamydia trachomatis. Lancet Public Health 2017; 2(4):e182-e190.

(27) Public Health England. Audit report on turnaround times: National Chlamydia Screening Programme. London: PHE; 2014.

(28) Lindberg LD, Maddow-Zimet I, Boonstra H. Changes in Adolescents' Receipt of Sex Education, 2006-2013. J Adolesc Health 2016; 58(6):621-7.

(29) Samkange-Zeeb F, Mikolajczyk RT, Zeeb H. Awareness and knowledge of sexually transmitted diseases among secondary school students in two German cities. J Community Health 2013; 38(2):293-300.

(30) Lim MS, Bowring AL, Gold J, Aitken CK, Hellard ME. Trends in sexual behavior, testing, and knowledge in young people; 2006-2011. Sex Transm Dis 2012; 39(11):831-4.

**Figure 1. Consort flow diagram for Test n Treat/TnT cluster randomised feasibility trial of rapid chlamydia tests and on-site treatment in six FE colleges**

**Number of colleges**

n = 6

**Number of students recruited and provided samples at baseline**

n = 509

**TnT**

3 colleges

259 students

**Control – no TnT**

3 colleges

250 students

**1 month TnT\***

33 students tested

**4 months TnT\***

26 students tested

**Reasons no data at 7 months follow up (n=108)**

* Lost to follow-up (n=84)
* Declined to provide sample/questionnaire (n=8)
* Withdrawn/ hung up (n=9)
* Agreed to provide sample but didn’t (n=7)

**7 months follow up**

**Total** – 151 students

**Samples** –119 students\*\*

**Questionnaire data** - 150 students\*\* \*

- College questionnaire (n=98)

- Email questionnaire (n=26)

- Telephone questionnaire (n=13)

- Limited telephone questionnaire (n=13\*\*\*\*)

**7 months follow up**

**Total** – 167 students

**Samples** – 145 students\*\*

**Questionnaire data** - 167 students

- College questionnaire (n=134)

- Email questionnaire (n=20)

- Telephone questionnaire (n=7)

- Limited telephone questionnaire (n=6\*\*\*\*)

**Reasons no data at 7 months follow up (n=83)**

* Lost to follow-up (n=64)
* Declined to provide sample/questionnaire (n=2)
* Withdrawn/ hung up (n=9)
* Agreed to provide sample but didn’t (n=8)

\*Five participants provided samples at both one and four months.

\*\* Two additional samples from each arm did not give a valid result

\*\*\* One participant only returned a sample but did not complete a questionnaire

\*\*\*\* Limited questionnaire data were collected while informing participants by telephone of a positive baseline test for five and two individuals in the intervention and control groups respectively.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1: Baseline characteristics of 509 Further Education college students allocated to intervention and control arms of the Test and Treat *C.trachomatis* screening trial**.   |  |  |  | | --- | --- | --- | | **Characteristic** | **Intervention** | **Control** | | **(n=259)** | **(n=250)** | |  |  |  | | **Male % (n)** | 49.8 (129) | 44.4 (111) | |  |  |  | | **Age median (IQR)** | 17.6 (16.8-18.6) | 18.0 (17.3-18.9 | |  |  |  | | **Ethnicity % (n)** |  |  | | White | 27.2 (70) | 25.5 (63) | | Black African/Black Caribbean/Black British | 48.6 (125) | 51.0 (126) | | Asian/Asian British | 5.1 (13) | 6.1 (15) | | Mixed/multiple ethnicities | 15.2 (39) | 12.6 (31) | | Other ethnic group | 3.9 (10) | 4.9 (12) | |  |  |  | | **Sexual Preference (females) % (n)** |  |  | | Sex with men only | 86.8 (112) | 89.9 (124) | | Sex with women only | 3.9 (5) | 1.4 (2) | | Sex with men and women | 4.7 (6) | 7.2 (10) | | Prefer not to say | 4.7 (6) | 1.4(2) | | **Sexual Preference (males) % (n)** |  |  | | Sex with men only | 3.9 (5) | 2.7 (3) | | Sex with women only | 93.0 (120) | 94.6 (105) | | Sex with men and women | 1.6 (2) | 2.7 (3) | | Prefer not to say | 1.6 (2) | 0.0 (0) | |  |  |  | | **Age at first sexual intercourse <16 years % (n)** | 44.8 (112) | 47.3 (112) | |  |  |  | | **Two or more partners in past 12 months % (n)** | 56.6 (145) | 53.5 (130) | |  |  |  | | **New sexual partner in past 6 months % (n)** | 55.5 (141) | 51.4 (128) | |  |  |  | | **Female contraception % (n)** |  |  | | Condoms | 56.2 (73) | 54.0 (75) | | Pill | 16.9 (22) | 20.9 (29) | | Implant/coil | 15.4 (20) | 17.3 (24) | | None | 20.0 (26) | 15.1 (21) | | Other | 2.3 (3) | 2.9 (4) | | **Condom use (male and female) % (n)** |  |  | | Always | 36.2 (92) | 36.0 (89) | | Usually | 17.7 (45) | 21.1 (52) | | Sometimes | 31.1 (79) | 26.3 (65) | | Never | 15.0 (38) | 16.6 (41) | | **Last STI check % (n)** |  |  | | Never | 46.1 (118) | 41.9 (103) | | In the past 6 months | 36.7 (94) | 35.8 (88) | | More than 6 months ago | 17.2 (44) | 22.4 (55) | | **STI history ever % (n)** |  |  | | *C.trachomatis* | 7.5 (19) | 8.9 (22) | | *N.gonorrhoeae* | 5.7 (14) | 4.2 (10) | | Other STI | 0.9 (2) | 1.3 (3) | | NSU | 0.4 (1) | 1.3 (3) | | Pelvic Inflammatory Disease in past 6 months (females only) | 2.4 (3) | 2.2 (3) | | **Symptoms in past 6 months (female) % (n)** |  |  | | Bleeding between periods | 17.5 (21) | 15.9 (21) | | Abnormal vaginal discharge | 11.9 (14) | 14.8 (19) | | Pelvic discomfort other than normal period pain | 7.0 (8) | 13.2 (17) | | Pain during sex | 17.4 (20) | 17.3 (23) | | **Symptoms in past 6 months (male) % (n)** |  |  | | Pain/ burning when urinating | 6.5 (8) | 7.4 (8) | | Discharge from your penis | 2.4 (3) | 1.9 (2) | | Pain or discomfort in testicles | 6.5 (8) | 4.7 (5) | | Pain/ burning from back passage | 2.5 (3) | 1.9 (2) | |  |  |  | | **Smokes cigarettes % (n)** | 34.3 (87) | 32.4 (81) | | **Alcohol-reports was drunk in past month % (n)** | 48.4 (123) | 48.3 (119) | |  |  |  | | **Visited GP in past 6 months % (n)** | 59.1 (149) | 61.6 (151) | | **Visited Sexual health clinic in past 6 mths % (n)** | 31.2 (79) | 29.6 (72) | | **Visited Walk-in clinic in past 6 months % (n)** | 29.1 (73) | 31.6 (77) | | **Visited A&E/hospital in past 6 months % (n)** | 36.0 (91) | 31.8 (78) | |  |  |  | | **Attended healthcare facility for sexual health reasons in the past 6 months % (n)** | 36.9 (94) | 35.4 (87) | | ***C.trachomatis* at baseline\* % (n)** | 7.1 (18) | 5.2 (13) | | ***N.gonorrhoeae* at baseline\* % (n)** | 1.2 (3) | 0 (0) |   \*Baseline samples were stored and tested after seven months.  Similar numbers of students were recruited from each college (intervention colleges n=84, 85, 90; total 259: control colleges n=83, 78, 89; total 250).  NSU: non-specific urethritis. GP: general practitioner. A&E: Accident and Emergency department | | | |
| **Table 2: Baseline characteristics of 259 intervention students who either attended TnT and provided samples, or did not attend TnT at 1 month and/or 4 months** | | |
| **Baseline characteristic** | **Attended TnT** | **Did not attend TnT** |
| **(n=54\*)** | **(n=205)** |
| **Male % (n)** |  |  |
|  | 48.1 (26) | 50.2 (103) |
|  |  |  |
| **Age median (IQR)** | 17.4 (16.7 to 18.7) | 17.7 (16.8 to 18.5) |
| **Ethnicity % (n)** |  |  |
| White | 28.8 (15) | 26.8 (55) |
| Black African/Black Caribbean/Black British | 51.9 (27) | 47.8 (98) |
| Asian/Asian British | 1.9 (1) | 5.9 (12) |
| Mixed/multiple ethnicities | 13.5 (7) | 15.6 (32) |
| Other ethnic group | 3.8 (2) | 3.9 (8) |
|  |  |  |
| **Sexual Preference (females) % (n)** |  |  |
| Sex with men only | 100.0 (27) | 83.3 (85) |
| Sex with women only | 0.0 (0) | 4.9 (5) |
| Sex with men and women | 0.0 (0) | 5.9 (6) |
| Prefer not to say | 0.0(0) | 5.9 (6) |
| **Sexual Preference (males) % (n)** |  |  |
| Sex with men only | 7.7 (2) | 2.9 (3) |
| Sex with women only | 84.6 (22) | 95.1 (98) |
| Sex with men and women | 7.7 (2) | 0.0 (0) |
| Prefer not to say | 0.0 (0) | 1.9 (2) |
|  |  |  |
| **Age first sex <16 years % (n)** | 44.2 (23) | 44.9 (89) |
|  |  |  |
| **Two or more partners in past 12 months % (n)** | 50.9 (27) | 58.1 (118) |
|  |  |  |
| **New partner in past 6 months % (n)** | 50.9 (27) | 56.7 (114) |
|  |  |  |
| **Female contraception % (n)** |  |  |
| Condoms | 67.9 (19) | 52.9 (54) |
| Pill | 14.3 (4) | 17.6 (18) |
| Implant/coil | 14.3 (4) | 15.7 (16) |
| None | 14.3 (4) | 21.6 (22) |
| Other | 7.1 (2) | 1.0 (1) |
| **Condom use (male and female) % (n)** |  |  |
| Always | 41.5 (22) | 34.8 (70) |
| Usually | 17.0 (9) | 17.9 (36) |
| Sometimes | 30.2 (16) | 31.3 (63) |
| Never | 11.3 (6) | 15.9 (32) |
|  |  |  |
| **Last STI check % (n)** |  |  |
| Never | 45.3 (24) | 46.3 (94) |
| In the past 6 months | 35.8 (19) | 36.9 (75) |
| More than 6 months ago | 18.9 (10) | 16.7 (34) |
| **STI ever % (n)** |  |  |
| *C.trachomatis* | 13.2 (7) | 6.0 (12) |
| *N.gonorrhoeae* | 8.2 (4) | 5.1 (10) |
| Other STI | 0.0 (0) | 1.0 (2) |
| NSU | 0.0 (0) | 0.5 (1) |
| Pelvic Inflammatory Disease in past 6 months | 11.1 (3) | 0.0 (0) |
| **Symptoms in past 6 months (female) % (n)** |  |  |
| Bleeding between periods | 25.0 (6) | 15.6 (15) |
| Abnormal vaginal discharge | 12.5 (3) | 11.7 (11) |
| Pelvic discomfort other than normal period pain | 8.7 (2) | 6.6 (6) |
| Pain during sex | 14.3 (3) | 18.1 (17) |
| **Symptoms in past 6 months (male) % (n)** |  |  |
| Pain/ burning when urinating | 4.0 (1) | 7.1 (7) |
| Discharge from your penis | 0.0 (0) | 3.1 (3) |
| Pain or discomfort in testicles | 8.0 (2) | 6.1 (6) |
| Pain/ burning from back passage | 4.2 (1) | 2.1 (2) |
|  |  |  |
| **Smokes cigarettes % (n)** | 22.6 (12) | 37.3 (75) |
|  |  |  |
|  |  |  |
| **Alcohol-reports was drunk in past month % (n)** | 43.2 (22) | 49.8 (101) |
|  |  |  |
| **Visited GP in past 6 months % (n)** | 53.8 (28) | 60.5 (121) |
| **Visited sexual health clinic in past 6 months % (n)** | 39.2 (20) | 29.2 (59) |
| **Visited Walk-in clinic in past 6 months % (n)** | 30.0 (15) | 28.9 (58) |
| **Visited A&E/hospital in past 6 months % (n)** | 27.5 (14) | 38.1 (77) |
|  |  |  |
| **Attended healthcare facility for sexual health reasons in past 6 months % (n)** | 46.2 (24) | 34.5 (70) |
| ***C.trachomatis* at baseline % (n)** | 3.7 (2) | 8.0 (16) |
| ***N.gonorrhoeae* at baseline % (n)** | 0.0 (0) | 1.5 (3) |

\* Five participants attended at both one and four months

**Table 3: Reported behaviours during the study from 7-month follow-up questionnaires**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | |  | | | |
|  | | | | | | | **Intervention** | | **Control** | |
| **Follow-up characteristics, % (n)** | | | | | | | **(n=150)** | | **(n=167)** | |
| **Follow up method** | | | College questionnaire | | | | 65.3 | (98) | 80.2 | (134) |
|  | | | Email questionnaire | | | | 17.3 | (26) | 12.0 | (20) |
| Telephone questionnaire | | | | | | | 8.7 | (13) | 4.2 | (7) |
| Limited telephone questionnaire | | | | | | | 8.7 | (13) | 3.6 | (6) |
|  | | | | | | |  |  |  |  |
| **Have they had sex with anyone new since last visit?** | | | | | Yes | | 49.3 | (73) | 54.5 | (91) |
| **Have they been tested for chlamydia or gonorrhoea outside the study?** | | | | |  | |  |  |  |  |
| Yes | | 29.3 | (44) | 25.1 | (42) |
|  | | | | | | |  |  |  |  |
| **Where did they get tested?** | | | | | | GP | 21.2 | (7) | 12.8 | (5) |
|  | Sexual health clinic | | | | | | 33.3 | (11) | 56.4 | (22) |
| Walk in clinic | | | | | | | 9.1 | (3) | 5.1 | (2) |
|  | Hospital | | | | | | 3.0 | (1) | 2.6 | (1) |
|  | College | | | | | | 27.3 | (9) | 17.9 | (7) |
|  | Other | | | | | | 6.1 | (2) | 5.1 | (2) |
|  | | | | | | |  |  |  |  |
| **Smoking (cigarettes per day)** | | | | None | | | 69.7 | (83) | 65.5 | (91) |
|  | | | | 1-10 | | | 25.2 | (30) | 30.9 | (43) |
|  | | | | More than 10 | | | 5.0 | (6) | 3.6 | (5) |
|  | | | | | | |  |  |  |  |
| **Vape (smoke electronic cigarettes)** | | | | | No | | 85.9 | (110) | 84.7 | (133) |
|  |  |  | | | Yes | | 6.3 | (8) | 4.5 | (7) |
| Occasionally | | | | | | | 7.8 | (10) | 10.8 | (17) |
|  | | | | | | |  |  |  |  |
| **Alcohol (number of times drunk in past month)** | | | | | None | | 61.7 | (79) | 51.3 | (80) |
| 1-4 times | | 28.9 | (37) | 41.0 | (64) |
|  | | | | | 5 or more | | 9.4 | (12) | 7.7 | (12) |
|  | | | | | | |  |  |  |  |
| **Visited GP in past 6 months** | | | | |  | | 56.4 | (75) | 49.4 | (79) |
| **Visited GUM clinic in past 6 months** | | | | |  | | 22.1 | (29) | 25.8 | (41) |
| **Visited Walk-in clinic in past 6 months** | | | | | | | 22.1 | (29) | 25.6 | (40) |
| **Visited A&E/hospital in past 6 months** | | | | | | | 28.8 | (38) | 23.1 | (37) |
| **Attended healthcare facility for sexual health reasons** | | | | | | | 15.1 | (39) | 17.2 | (43) |

**Supplementary Table 1. Baseline characteristics of 509 participants who did or did not provide a valid sample at 7 months follow-up.**

|  |  |  |
| --- | --- | --- |
| **Baseline characteristic** | **Sample provided at follow-up** | **No sample at follow-up** |
|  | **(n=264)** | **(n=245)** |
| **Male % (n)** |  |  |
|  | 47.3 (125) | 46.9 (115) |
|  |  |  |
| **Age median (IQR)** | 17.9 (17.1 to 18.7) | 17.9 (16.9 to 18.7) |
| **Ethnicity % (n)** |  |  |
| White | 26.6 (69) | 26.6 (64) |
| Black African/Black Caribbean/Black British | 52.1 (135) | 47.3 (116) |
| Asian/Asian British | 6.2 (16) | 4.9 (12) |
| Mixed/multiple ethnicities | 10.4 (27) | 17.6 (43) |
| Other ethnic group | 4.6 (12) | 4.1 (10) |
|  |  |  |
| **Sexual Preference (females) % (n)** |  |  |
| Sex with men only | 87.7 (121) | 89.1 (115) |
| Sex with women only | 1.4 (2) | 3.9 (5) |
| Sex with men and women | 6.5 (9) | 5.4 (7) |
| Prefer not to say | 4.3 (6) | 1.6 (2) |
| **Sexual Preference (males) % (n)** |  |  |
| Sex with men only | 4.0 (5) | 2.6 (3) |
| Sex with women only | 92.8 (116) | 94.8 (109) |
| Sex with men and women | 2.4 (3) | 1.7 (2) |
| Prefer not to say | 0.8 (1) | 0.9 (1) |
|  |  |  |
| **Age first sex <16 years % (n)** | 42.3 (107) | 50.0 (117) |
|  |  |  |
| **Two or more partners in past 12 months % (n)** | 53.1 (136) | 57.2 (139) |
|  |  |  |
| **New partner in past 6 months % (n)** | 50.4 (132) | 56.8 (137) |
|  |  |  |
| **Female contraception % (n)** |  |  |
| Condoms | 57.6 (80) | 52.3 (68) |
| Pill | 22.3 (31) | 15.4 (20) |
| Implant/coil | 14.4 (20) | 18.5 (24) |
| None | 16.5 (23) | 18.5 (24) |
| Other | 2.9 (4) | 2.3 (3) |
| **Condom use (male and female) % (n)** |  |  |
| Always | 37.1 (99) | 35.1 (85) |
| Usually | 18.1 (47) | 20.7 (50) |
| Sometimes | 31.7 (82) | 25.6 (62) |
| Never | 13.1 (34) | 18.6 (45) |
|  |  |  |
| **Last STI check up % (n)** |  |  |
| Never | 46.5 (121) | 41.3 (100) |
| In the past 6 months | 35.4 (92) | 37.2 (90) |
| More than 6 months ago | 18.1 (47) | 21.5 (52) |
| **STI history % (n)** |  |  |
| *C.trachomatis* | 6.5 (17) | 10.0 (24) |
| *N.gonorrhoeae* | 3.1 (8) | 6.9 (16) |
| Other STI | 0.8 (2) | 1.3 (3) |
| NSU | 0.4 (1) | 1.3 (3) |
| Pelvic Inflammatory Disease in past 6 months | 2.9 (4) | 1.6 (2) |
| **Symptoms in past 6 months (female) % (n)** |  |  |
| Bleeding between periods | 14.8 (19) | 18.5 (23) |
| Abnormal vaginal discharge | 16.0 (20) | 10.7 (13) |
| Pelvic discomfort other than normal period pain | 10.6 (13) | 10.0 (12) |
| Pain during sex | 18.3 (23) | 16.4 (20) |
|  |  |  |
| **Symptoms in past 6 months (male) % (n)** |  |  |
| Pain/ burning when urinating | 7.4 (9) | 6.4 (7) |
| Discharge from your penis | 1.7 (2) | 2.8 (3) |
| Pain or discomfort in testicles | 5.0 (6) | 6.4 (7) |
| Pain/ burning from back passage | 2.5 (3) | 1.9 (2) |
|  |  |  |
| **Smokes cigarettes % (n)** | 27.5 (72) | 39.7 (96) |
|  |  |  |
| **Alcohol-reports was drunk in past month % (n)** | 46.3 (120) | 50.6 (122) |
|  |  |  |
| **Visited GP in past 6 months % (n)** | 62.0 (160) | 58.5 (140) |
| **Visited sexual health clinic in past 6 months % (n)** | 28.8 (74) | 32.2 (77) |
| **Visited Walk-in clinic in past 6 months % (n)** | 32.3 (83) | 28.2 (65) |
| **Visited A&E/hospital in past 6 months % (n)** | 31.5 (81) | 36.5 (88) |
|  |  |  |
| **Attended healthcare facility for sexual health reasons in past 6 months % (n)** | 35.1 (91) | 37.2 (90) |
|  |  |  |
| ***C.trachomatis* at baseline % (n)** | 3.8(10) | 8.7 (21) |
| ***N.gonorrhoeae* at baseline % (n)** | 0.4 (1) | 0.8 (2) |

**Supplementary Table 2: Prevalence of *C. trachomatis* at baseline and final seven months follow-up in three intervention and three control colleges**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Intervention college 1** | **Intervention college 2** | **Intervention**  **college 3** | **Control**  **college 1** | **Control college 2** | **Control college 3** |
| **Prevalence of *C.trachomatis* at baseline**  **% (n/N)** | 8.3  (7/84) | 8.3  (7/84) | 4.6  (4/87) | 8.4  (7/83) | 1.3  (1/77) | 5.7  (5/88) |
| **Prevalence of *C.trachomatis* at seven months follow up**  **% (n/N)** | 5.1  (2/39) | 7.7  (3/39) | 2.4  (1/41) | 4.1  (2/49) | 6.3  (3/48) | 10.4  (5/48) |

\*Only five students provided samples at TnT at both one and four months.

\*\* One participant only returned a sample and did not complete a questionnaire

\*\*\* Questionnaire data were collected while informing participants of a positive baseline test for five and two individuals in the intervention and control groups respectively.